AMRN Share Price Performance
US$14.43
14.43 (0.00%)
15.4% overvalued intrinsic discount
US$12.50
Fair Value
Price US$14.43
AnalystConsensusTarget US$12.50
Fair ValueUS$12.50
Share Pricen/a
Narrative Update • May 21
Amarin Corporation plc Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
AMRN Community Narratives
AN
Fair Value
·Fair Value US$12.5 15.4% overvalued intrinsic discount
International Growth With Recordati Will Face Risks And Rewards
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
International Growth With Recordati Will Face Risks And Rewards
Amarin is leaning on overseas partners to keep its heart medicine growing as sales weaken at home, but that plan depends on tricky approvals, pricing pressure, and strong execution in each new country. Learn why a move toward partner royalties and a one‑product lineup could either steady the business or make results swing more than investors expect.Read more
AN
US$12.5
15.4% overvalued intrinsic discount
Fair Value
Profit Margin
20.16%
Future PE
8.12x
Price in 2029
US$14.95
Trending Discussion
Recently Updated Narratives
AN
AMRN: Guideline Support Will Not Prevent Future Revenue And Margin Pressure
Fair Value: US$12.5 15.4% overvalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Amarin Corporation plc Key Details
About AMRN
- Founded
- 1989
- Employees
- 80
- CEO
- WebsiteView website
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
